Related Experiment Videos
[Transferability of meropenem to cerebrospinal fluid in rabbits with meningitis caused by Staphylococcus aureus]
Abstract:
The transferability of meropenem (MEPM) to cerebrospinal fluid (CSF) was studied employing rabbits with experimental meningitis caused by Staphylococcus aureus. The mean serum concentration was 93.1 +/- 13.5 micrograms/ml at 15 minutes after intravenous administration of MEPM at a dose level of 100 mg/kg. The mean concentration in CSF was maximum at 15 minutes after administration at 4.42 +/- 2.24 micrograms/ml. Pharmacokinetic parameters calculated from these values were as follows: Cmax (CSF/serum) 4.75%, AUC (CSF/serum) 10.4% between 15 and 60 minutes, 13.9% between 15 and 120 minutes and 15.7% between 15 and 180 minutes, T 1/2 for MEPM in CSF: 50.9 minutes, T 1/2 (CSF/serum): 2.19. In comparison to those of imipenem which were obtained in the same way, the transferability of MEPM was similar and in consideration of the antimicrobial potency against the main pathogens of meningitis, it appears worth-while of running clinical trials for this drug.
Insights
Meropenem (MEPM) effectively transfers to cerebrospinal fluid (CSF) in rabbits with Staphylococcus aureus meningitis. Its pharmacokinetic profile suggests potential for clinical trials in treating bacterial meningitis.
Area of Science:
- Pharmacology
- Infectious Diseases
- Neuroscience
Background:
- Bacterial meningitis remains a critical global health concern, necessitating effective antibiotic penetration into the central nervous system.
- Meropenem (MEPM) is a broad-spectrum carbapenem antibiotic with established efficacy against various bacterial pathogens.
Purpose of the Study:
- To evaluate the transferability and pharmacokinetic properties of meropenem (MEPM) into cerebrospinal fluid (CSF) in a rabbit model of Staphylococcus aureus meningitis.
- To compare the CSF penetration of MEPM with that of imipenem.
Main Methods:
- Experimental meningitis was induced in rabbits using Staphylococcus aureus.
- Intravenous administration of MEPM at a dose of 100 mg/kg.
- Serum and CSF concentrations of MEPM were measured at various time points post-administration.
- Pharmacokinetic parameters, including Cmax, AUC, and T 1/2, were calculated for both serum and CSF.
Main Results:
- Mean peak serum concentration of MEPM was 93.1 ± 13.5 µg/ml at 15 minutes.
- Mean peak CSF concentration of MEPM was 4.42 ± 2.24 µg/ml at 15 minutes.
- CSF/serum ratios for Cmax and AUC indicated significant penetration, with AUC (CSF/serum) reaching 15.7% by 180 minutes. The elimination half-life (T 1/2) in CSF was 50.9 minutes.
Conclusions:
- Meropenem demonstrates favorable transferability into the CSF in a rabbit model of bacterial meningitis.
- The pharmacokinetic profile of MEPM in CSF is comparable to that of imipenem.
- Given its antimicrobial potency against key meningitis pathogens, MEPM warrants further investigation in clinical trials for meningitis treatment.